Sign In
Buy XLRN
$178.75
+0 (+0%)
At Close: May 27, 2022
Merck to buy Acceleron for about $11.5 billion in rare disease drugs push
07:04am, Thursday, 30'th Sep 2021
Merck & Co will buy drugmaker Acceleron Pharma Inc for about $11.5 billion, the companies said on Thursday, as the U.S. pharmaceutical giant looks to beef up its portfolio with drugs for rare diseases
Acceleron (XLRN) Stock Up on Takeover Rumors for $11 Billion
11:36am, Tuesday, 28'th Sep 2021
Acceleron (XLRN) up on rumors of a potential acquisition by a pharma giant for $11 billion or $180 per share.
Merck Reportedly Lead Bidder In $11B Acceleron Buyout: WSJ
06:04am, Tuesday, 28'th Sep 2021
The Wall Street Journal reported that Merck & Co Inc (NYSE: MRK) is in advanced talks to acquire Acceleron Pharma Inc (NASDAQ: XLRN), citing people familiar with the matter. The deal for Acceler
The Wall Street Journal: Merck nears deal for rare-disease-drug maker Acceleron
03:20am, Tuesday, 28'th Sep 2021
Merck is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giant's rare-disease business.
Merck nears deal to acquire Acceleron Pharma
10:19pm, Monday, 27'th Sep 2021
Merck & Co. is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giant's rare-disease business.
Bristol-Myers Reportedly Most Likely Buyer of Acceleron Pharma
06:08pm, Monday, 27'th Sep 2021
Bristol-Myers Squibb Co. ( BMY , Financial) is the odds-on favorite to acquire Acceleron Pharma Inc. ( XLRN , Financial) and the rights to its two promising drugs, reported Bloomberg.
Merck in advanced talks to buy Acceleron Pharma
05:52pm, Monday, 27'th Sep 2021
Merck & Co is in advanced talks to acquire drugmaker Acceleron Pharma Inc, the Wall Street Journal reported https://www.wsj.com/articles/merck-nears-deal-to-acquire-acceleron-pharma-11632778405?mod=la
Acceleron's stock gains 3.9% on acquisition report
09:07am, Monday, 27'th Sep 2021
Shares of Acceleron Pharma Inc. XLRN, +4.89% gained 3.9% in premarket trading on Monday after Bloomberg reported Friday that an unnamed buyer is considering spending $11 billion to buy the company. Ac
Acceleron In Advanced $11B Buyout Talks: Bloomberg
05:53am, Monday, 27'th Sep 2021
Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is potentially in advanced talks for an $11 billi
Why Acceleron Pharma Stock Jumped This Week
12:48pm, Saturday, 25'th Sep 2021
Buyout rumors are swirling around this mid-cap biotech company.
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q2 2021 Results - Earnings Call Transcript
10:20am, Sunday, 08'th Aug 2021
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q2 2021 Results - Earnings Call Transcript
Acceleron Pharma (XLRN) Reports Q2 Loss, Misses Revenue Estimates
07:01pm, Thursday, 05'th Aug 2021
Acceleron (XLRN) delivered earnings and revenue surprises of -14.13% and -10.25%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Acceleron Pharma: Q2 Earnings Insights
05:37pm, Thursday, 05'th Aug 2021
Shares of Acceleron Pharma (NASDAQ:XLRN) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 208.82% over the past year to ($1.05), which
Acceleron Reports Second Quarter 2021 Financial Results
04:01pm, Thursday, 05'th Aug 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics
Acceleron Announces Second Quarter 2021 REBLOZYL® Net Sales
07:10am, Wednesday, 28'th Jul 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics
